Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines
- PMID: 11564809
- DOI: 10.4049/jimmunol.167.7.3910
Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines
Abstract
A respiratory syncytial virus (RSV) vaccine will need to be administered by 1 mo of age to protect young infants; therefore, it will need to be effective in the presence of maternally acquired RSV Abs. In the present study, the immunogenicity and efficacy of two live attenuated RSV vaccine candidates of different level of attenuation were evaluated in mice passively immunized with varying quantities of RSV Abs. The replication of the RSV vaccines was suppressed in the lower, but not the upper, respiratory tract of the passively immunized mice. Immunization with either vaccine candidate was highly efficacious against challenge with wild-type RSV in both passively immunized and control mice. Nonetheless, a high level of immunity was seen even in passively/actively immunized animals that failed to develop a humoral immune response, suggesting that T cells mediated the immunity. Depletion of CD4+ and CD8+ T cells in passively/actively immunized and control animals at the time of challenge with wild-type RSV demonstrated that CD4+ and CD8+ T cells made significant independent contributions to the restriction of replication of RSV challenge virus in both the upper and lower respiratory tracts. Although passively acquired serum RSV Abs suppressed the primary systemic and mucosal Ab responses of IgM, IgG, and IgA isotypes, B lymphocytes were nevertheless primed for robust secondary Ab responses. Thus, immunity mediated by CD4+ and CD8+ T cells and Abs can be readily induced in mice by live RSV vaccine candidates in the presence of physiologic levels of RSV neutralizing Abs.
Similar articles
-
A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.PLoS One. 2015 Mar 20;10(3):e0119509. doi: 10.1371/journal.pone.0119509. eCollection 2015. PLoS One. 2015. PMID: 25793508 Free PMC article.
-
Inferior immunogenicity and efficacy of respiratory syncytial virus fusion protein-based subunit vaccine candidates in aged versus young mice.PLoS One. 2017 Nov 28;12(11):e0188708. doi: 10.1371/journal.pone.0188708. eCollection 2017. PLoS One. 2017. PMID: 29182682 Free PMC article.
-
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.J Virol. 2002 Feb;76(3):1089-99. doi: 10.1128/jvi.76.3.1089-1099.2002. J Virol. 2002. PMID: 11773385 Free PMC article.
-
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x. Immunol Rev. 2011. PMID: 21198670 Free PMC article. Review.
-
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.
Cited by
-
A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19.Transfus Apher Sci. 2020 Oct;59(5):102936. doi: 10.1016/j.transci.2020.102936. Epub 2020 Sep 5. Transfus Apher Sci. 2020. PMID: 32919880 Free PMC article. Review.
-
Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.Immunology. 2010 Dec;131(4):549-55. doi: 10.1111/j.1365-2567.2010.03327.x. Immunology. 2010. PMID: 20673239 Free PMC article.
-
Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report.J Med Virol. 2021 Mar;93(3):1678-1686. doi: 10.1002/jmv.26537. Epub 2020 Oct 5. J Med Virol. 2021. PMID: 32965715 Free PMC article.
-
Mucosal immunisation and immunoprophylaxis as potential strategies for prevention of SARS.Lancet. 2004 Jun 26;363(9427):2102-3. doi: 10.1016/S0140-6736(04)16535-5. Lancet. 2004. PMID: 15220029 Free PMC article. No abstract available.
-
Progress in respiratory virus vaccine development.Semin Respir Crit Care Med. 2011 Aug;32(4):527-40. doi: 10.1055/s-0031-1283289. Epub 2011 Aug 19. Semin Respir Crit Care Med. 2011. PMID: 21858754 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous